Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the research. That's according to company-sponsored studies ...
Fasenra’s EU approval closely follows its US approval in September. The antibody drug is also approved in more than 80 countries as an add-on maintenance treatment for severe eosinophilic asthma (SEA) ...
“Fasenra has been a well-established treatment for many years in thousands of people with severe eosinophilic asthma and we are pleased to now offer a much-needed treatment option for those ...
Fasenra has been a well-established treatment for many years in thousands of people with severe eosinophilic asthma and we are pleased to now offer a much-needed treatment option for those living with ...
The pollution poses a severe health threat to residents since the river provides more than half of the Indian capital's water. New Delhi also has some of the world’s most polluted air every year ...
Almost 50% of patients with EGPA also suffer from severe eosinophilic asthma and often experience sinus and nasal symptoms. AstraZeneca bioPharmaceuticals business unit executive vice-president Ruud ...
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis ...
Search Engine Land » PPC » Amazon non-endemic ads: Winning strategies for service-based businesses Chat with SearchBot Please note that your conversations will be recorded. SearchBot ...
AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback